We offer disruptive solutions to improve performance and cost of biological processes while enhancing human interactions with instruments that accelerate the biologic development timeline.
Disruptive solutions that accelerate the biologic development timeline
Human therapies are adapting to tackle increasingly complex immunological diseases and conditions. These therapies often rely on tightly controlled cell cultures in order to produce therapeutic drugs efficiently, such as monoclonal antibodies or culture of the patient’s own genetically-engineered cells, as part of an autologous cell therapy workflow.
The development of new biological processes is often carried out by scientists who want to be able to rapidly and reliably characterise culture performance under different process conditions. The commercial viability of these new therapies is heavily dependent on the productivity of the biology when later scaled out or scaled up. New sensors and improved user interactions with equipment can greatly speed up the pace of development and improve time to market for new therapies.
We offer disruptive solutions to improve performance and cost while enhancing human interactions with instruments that accelerate the biologic development timeline.
Your biology. Enabled.
Life science instruments and diagnostic systems are moving towards user-friendly and low-cost systems often designed for space-limited lab or clinic environments.
Recognising this, we offer specialised platforms and technologies as well as bespoke solutions, that enable and accelerate the development of successful systems in these markets for our clients.
With our fusion of science insight and system engineering, we address bottlenecks in the translation of biological processes, including technologies for rapid and accurate thermal control, tools for lysis and transfection, and manufacturing innovation in bioprinting.